JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

188.28 -5.12

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

187.96

Massimo

201.47

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+10% upside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.7B

10B

Apertura precedente

193.4

Chiusura precedente

188.28

Notizie sul Sentiment di mercato

By Acuity

50%

50%

151 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 feb 2026, 00:00 UTC

Azioni calde

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 feb 2026, 22:55 UTC

Utili

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 feb 2026, 21:44 UTC

Utili

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 feb 2026, 21:39 UTC

Utili

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 feb 2026, 00:00 UTC

Utili

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 feb 2026, 00:00 UTC

Utili

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 feb 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 feb 2026, 23:45 UTC

Utili

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 feb 2026, 23:32 UTC

Discorsi di Mercato

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 feb 2026, 22:59 UTC

Acquisizioni, Fusioni, Takeovers

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 feb 2026, 22:30 UTC

Utili

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 feb 2026, 22:30 UTC

Utili

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 feb 2026, 22:21 UTC

Utili

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 22:17 UTC

Discorsi di Mercato

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 feb 2026, 22:15 UTC

Discorsi di Mercato

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 feb 2026, 22:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

4 feb 2026, 21:53 UTC

Utili

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 feb 2026, 21:51 UTC

Utili

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 feb 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

4 feb 2026, 21:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

4 feb 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 feb 2026, 21:45 UTC

Utili

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 feb 2026, 21:44 UTC

Utili

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 feb 2026, 21:43 UTC

Utili

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 feb 2026, 21:41 UTC

Utili

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 21:36 UTC

Discorsi di Mercato

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 feb 2026, 21:30 UTC

Utili

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Utili

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Utili

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

10% in crescita

Previsioni per 12 mesi

Media 221.55 USD  10%

Alto 265 USD

Basso 170 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

9

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

151 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat